ModernaTX takes up option to develop, sell Avacta's affimer technology

Writer, Stock Market Wire
Monday, February 4, 2019 - 08:32

Avacta Group said Monday that ModernaTX had exercised its option to enter into an exclusive licensing agreement with respect to certain Affimer molecules that had been generated through collaboration between the two companies.

Under the terms of the agreement, Avacta was in line to receive undisclosed payments based on future clinical development milestones and royalties in connection with future product sales.

In 2015, Avacta and Moderna entered into a collaboration, license and option agreement under which Moderna was granted exclusive access to Avacta's Affimer technology for certain collaboration targets.

It was also graded the option to enter into exclusive license agreements on pre-agreed terms to further research, develop and commercialize Affimers selected by Moderna.

'I am delighted to report that Moderna has exercised its option to enter into this exclusive license agreement with respect to certain Affimer molecules that have been generated through our collaboration. This is further strong validation of the potential of the Affimer drug platform to generate differentiated therapeutic molecules for development,' said Dr Alastair Smith, Avacta Group Chief Executive Officer.

At 8:32am: (LON:AVCT) Avacta Group PLC share price was +2.3p at 44.8p

Related content

Avacta appoints Jose Saro as chief medical officer

Avacta Group said it had appointed Jose Saro as its new chief medical officer.

Saro joined the group from Roche, where he was senior translational...

Wed, 12/12/2018 - 14:38

Avacta forms therapeutics development pact with South Korea's LG Group

Avacta Group said it had formed a development partnership and license agreement with a unit of South Korea's LG Group for biotherapeutics in several disease...

Mon, 10/12/2018 - 14:09

Avacta to present pre-clinical development data at Lisbon conference

Biotherapeutics and reagents developer Avacta Group said chief scientific officer Amrik Basran would present at a conference in Lisbon this week.

Basran would on Wednesday...

Mon, 12/11/2018 - 13:43

Avacta Group losses widen as R&D investment jumps 31%

Biotherapeutics and reagents producer Avacta Group said Tuesday annual losses widened following an acceleration in research and development investment.

For the 12 months to 21...

Tue, 02/10/2018 - 09:39

Avacta forms collaboration pact with Tufts University in Boston

Biotherapeutics and reagents developer Avacta Group said it had formed a co-development partnership with Bach BioSciences, a company commercialising research conducted at Tufts University School...

Tue, 24/07/2018 - 14:14